Salute e Benessere

Pharming Group reports on results of the 2025 Extraordinary General Meeting of…

Leiden, the Netherlands, March 4, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) announces today that the Extraordinary General Meeting of Shareholders (EGM) has adopted all proposals on the EGM agenda.Shareholders approved the appointment of Mr. Fabrice Chouraqui as Executive Director and Chief Executive Officer for a term of four years. As a result, Mr. Chouraqui succeeds Mr. Sijmen de Vries with immediate effect. To ensure a smooth...

Mural Health and ICON Announce Partnership to Enhance Participant and Site…

"From our very first conversations with ICON, we were highly impressed by their commitment to patient care and innovation," said Sam Whitaker, CEO of Mural Health. "This partnership represents a shared vision of removing barriers to trial participation and advancing participation financial neutrality, while eliminating the need for site staff to manage highly manual, error-prone, and time-consuming administrative activities." "From our very first conversations with ICON…

The King of Bollywood teams up with the King of Basmati

Speaking about the association, Mr. Shah Rukh Khan said, "I'm glad to partner with DAAWAT®, where passion and commitment to excellence come together, inspiring people to bring out their finest in every meal and every moment." Speaking about the association, Mr. Shah Rukh Khan said,"I'm glad to partner with DAAWAT ®, where passion and commitment to excellence come together, inspiring people to bring out their finest in every meal and every moment." Mr.Ashwani Arora, Managing…

Tiziana Life Sciences Files Investigational New Drug Application with FDA for…

TLSA ) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced the submission of its Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for a phase 2 clinical trial in ALS. This pivotal step marks a significant advancement in the company's commitment to advance a new treatment approach...

Evaxion to present at numerous upcoming conferences

Evaxion will provide company and scientific updates at conferences in both the US and Europe during the coming weeks and monthsCOPENHAGEN, Denmark, March 4, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will be presenting at several investor and scientific conferences in March and throughout the second quarter of 2025.Evaxion will be providing company and scientific updates as well...

Milo Surpasses $65 Million in Crypto Mortgage Volume

"Our mission is to bridge digital assets with real estate and build long term wealth," said Josip Rupena, CEO and founder of Milo. "For many of our clients, fiat liquidity alone isn't sufficient to qualify for a mortgage. We're proud to redefine mortgage eligibility by allowing their Bitcoin wealth to count. As Bitcoin demand continues to rise, our solution becomes even more essential, enabling our clients to keep their Bitcoin forever and finally buy a home." "Our…

AC Immune to Participate in Upcoming Investor Conferences

AC Immune to Participate in Upcoming Investor ConferencesLausanne, Switzerland, March 4, 2025– AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that the company's management will participate in the following investor conferences in March:Leerink Partners 2025 Global Healthcare Conference, Management will participate in investor meetings on March 10, 2025 Barclays 27th Annual...

The Chinese carbon ion center Heyou Hospital selects RayStation

In 2021, Heyou Hospital bought a combined Hitachi carbon ion and proton machine. This will now be complemented with RayStation, which will also be used for treatment planning for the hospital's conventional photon treatment machines. In 2021, Heyou Hospital bought a combined Hitachi carbon ion and proton machine. This will now be complemented with RayStation, which will also be used for treatment planning for the hospital's conventional photon treatment machines. Ion beam therapy is the most...

IBA and Apollo Hospitals sign a term sheet for one Proteus®ONE system plus a…

Louvain-La-Neuve, Belgium, March 04, 2025 –IBA(Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announces it has signed a term sheet with Apollo Hospitals Enterprise Limited (AHEL) for the supply of one Proteus ® ONE 1compact proton therapy solution plus a second one in option. Apollo will therefore expand access to proton therapy in India. The term sheet was...

KFSHRC's Dr. Jackie Ying Named in Forbes 50 Over 50 Global 2025 List

From 400 Research Papers to 200 Patents, Her Visionary Leadership is Shaping the Future of KFSHRC RIYADH, Saudi Arabia, March04, 2025(GLOBE NEWSWIRE) -- Dr. Jackie Ying, Executive Director of Research & Innovation at King Faisal Specialist Hospital & Research Centre (KFSHRC) has been recognized in the Forbes 50 Over 50 Global 2025 list. This prestigious recognition celebrates influential women who have demonstrated exceptional leadership, innovation, and global impact in their...

Briya Expands Access to European Real-World Data Through Strategic Partnership…

While RWD is increasingly essential for driving medical innovation, access to high-quality European data remains complex. This partnership addresses that gap by enabling global researchers to incorporate diverse Italian datasets into real-world evidence (RWE) studies, ultimately enhancing inclusion, refining clinical insights, and improving patient outcomes. Briya's platform adheres to all local and global compliance regulations including the European GDPR and provides unparalleled access to…

AB Science: Article from the leading publication Life Sciences Magazine…

PRESS RELEASEARTICLE FROM THE LEADING PUBLICATION LIFE SCIENCES MAGAZINE FEATURING AB SCIENCE'S MASITINIB AND ITS PHASE 3 PRINCIPAL INVESTIGATOR, THE NEUROLOGIST PATRICK VERMERSCHParis, March 04, 2025, 8.30am CET Professor Patrick Vermersch is a distinguished neurologist considered as one of the most influential key opinion leaders in his field According to Professor Patrick Vermersch, mast and microglia cells' pro-inflammatory activity could play a catalyst role in the...

Casino Group: Termination and implementation of a liquidity contract

Termination of the liquidity contract of Casino, Guichard-Perrachon Paris, 4 March 2025It is reminded that the liquidity contract entrusted to Rothschild Martin Maurel had been suspended on 11 June 2024. This contract has been terminated on 10 February 2025 by Casino, Guichard-Perrachon. At the close of trading on June 11, 2024, the following resources were recorded on the liquidity account: 1,875,000 shares and 14,313,545.45 euros. The number of shares has been reduced to 18,750...

JIGOO V700: The Revolutionary Cordless Vacuum Cleaner Station to Free Your Hands…

The JIGOO V700 features an all-in-one station that automatically cleans the filter, collects dust from the dust cup, and transfers it to the dust bag without manual operation. After dust collection, the vacuum recharges automatically. This innovative design ensures a hands-free and easy cleaning experience. The JIGOO V700features an all-in-one station that automatically cleans the filter, collects dust from the dust cup, and transfers it to the dust bag without manual operation. After dust...

ONWARD Medical to Advance Parkinson's Disease Pipeline with Support from The…

The Michael J. Fox Foundation for Parkinson's Research is supporting a study addressing mobility challenges in Parkinson's disease; the first participant was enrolled in late 2024A US Department of Defense grant will support a study addressing blood pressure instability; first enrollment is expected in 1H 2025These studies both explore whether the ONWARD ARC-IM System has the potential to offer benefit beyond spinal cord injury EINDHOVEN, the Netherlands, March04, 2025(GLOBE...

Full Year Trading Update

Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, March 4, 2025–Santhera Pharmaceuticals (SIX: SANN) today provides a trading update for the fiscal year 2024 and an outlook for 2025 and beyond.Dario Eklund, CEO of Santhera said:"The year 2024 has been a transformational year for Santhera as we strengthened our financial position and advanced the commercial roll out of AGAMREE® (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in key European...

Idorsia announces financial results for 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – March 4, 2025Idorsia Ltd (SIX: IDIA) today announced its financial results for 2024. Business highlights 2024 Viatris collaboration : Global research and development collaboration, focused on the development and commercialization of selatogrel and cenerimod entered in March 2024. QUVIVIQ™ (daridorexant): Outstanding launch dynamic in France, and a strong performance in Germany accelerate sales in 2024 – Total...

Elsevier announces expansion to their flagship clinical decision support…

Seamless workflows are crucial for doctors as they enable them to focus more on patient care, reduce time-consuming administrative tasks, and access relevant information efficiently. To serve the needs of busy clinicians, ClinicalKey AI is launching new workflow integrations in the electronic health record (EHR) with Epic[1] and into the health information technology (HIT) space with iPrescribe by DrFirst, along with a new mobile app available for Apple and Android users. Seamless workflows…

Raziel and Fosun Pharma (by JuveStar an affiliate company of Fosun Pharma)…

Raziel Therapeutics and Tianjin JuveStar Biotech Co., Ltd., (JuveStar), a company invested and incubated by the venture capital arm of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma, stock code: 600196.SH, 02196.HK), partnered with Raziel Therapeutics to develop RZL-012 and JuveStar holds the commercial rights for RZL-012 in Greater China. A phase 3 study will be initiated in China during the upcoming few weeks. JuveStar will be responsible for conducting the phase 3 study, while…

BioVaxys Technology Corp. Granted Management Cease Trade Order

While every effort is being made to make the Required Filings as soon as possible, one of the factors contributing to the delay is the recent acquisition of all intellectual property, immunotherapeutics platform Technology, and clinical stage assets of the former IMV Inc. completed on February 16, 2024. The purchase involved the acquisition of 120 patents, and it is taking longer than expected for the auditor to complete its review and valuation of the patents. The Company expects that its…

Global In Situ Hybridization Market to Grow at a CAGR of ~7% by 2032 |…

Key Takeaways from the In Situ Hybridization Market Report Key Takeaways from the In Situ Hybridization Market Report To read more about the latest highlights related to the in situ hybridization market, get a snapshot of the key highlights entailed in theGlobal In Situ Hybridization Market Report In Situ Hybridization Overview In situ hybridization (ISH) is a powerful laboratory technique used to detect and localize specific nucleic acid sequences within intact tissue...

Nyxoah to Participate in the Oppenheimer 35th Annual Healthcare MedTech &…

NyxoahtoParticipateinthe Oppenheimer35 th AnnualHealthcareMedTech& Services ConferenceMont-Saint-Guibert, Belgium – March 3, 2025, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH)(“Nyxoah” or the “Company”), that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation, today announced that the Company will participate in the Oppenheimer 35 thAnnual Healthcare MedTech & Services Conference,...

Teva to Present at Barclays Global Healthcare Conference and Leerink Partners…

Barclays 27 thAnnual Global Healthcare ConferenceTuesday, March 11, 2025, at 8:00 am ETLeerink Partners Global Healthcare ConferenceWednesday, March 12, 2025, at 8:40 am ETTo access a live webcast of the presentation, visit Teva's Investor Relations website athttps://ir.tevapharm.com/Events-and-Presentations.An archived version of the webcast will be available within 24 hours after the end of the live discussion. About Teva Teva Pharmaceutical Industries Ltd...

Full-Year 2024 Results - Progress on the implementation of the FOCUS-27 plan…

Press Release Paris, 3 rdMarch, 2025Full-year 2024 results 1 : Operational resilience and strong increase in Free Cash Flow before financing in a challenging environment Net sales down 10.0% to €911.9 million, driven by lower volumes for Sanofi and the suspension of production at Brindisi, only partly offset by encouraging commercial momentumCore EBITDA at €50.4m, with margin down 370bps year-on-year to 5.5%, due notably to unfavorable fixed cost impact€(43...

Altri Comunicati